Ketone Body Metabolic Enzyme OXCT1 Regulates Prostate Cancer Chemoresistance
Abstract
Analysis of needle biopsy samples revealed that OXCT1 was upregulated in a subset of patients and the upregulation was associated with chemotherapy resistance. In vitro analysis showed that OXCT1 was overexpressed in various prostate cancer cell lines compared to benign prostate cells. OXCT1 stable knockdown cell lines in C42B, DU145 and PC3 were established. The optimal docetaxel doses and treatment time were determined. OXCT1 knockdown cells showed lower proliferation and higher sensitivity to docetaxel treatment. Cellular metablolic endpoints such as ATP and ROS were altered by ketone body supplementation. These results confirmed our hypothesis that OXCT1 plays important role prostate cancer chemotherapy sensitivity.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2014
- Accession Number
- ADA613410
Entities
People
- Qiong Liu
Organizations
- Oregon Health & Science University